The content of this meeting is intended for UK Healthcare Professionals only. This meeting has been developed, organised, and funded by Eli Lilly and Company. The speakers have been selected, briefed and paid an honorarium by Lilly.
Lilly products will be discussed at this meeting.
Adverse event reporting can be found below and Jaypirca prescribing information can be found here.
Haem Matters is a national educational meeting bringing together healthcare professionals in haematology to explore current challenges in practice through expert-led presentations, real-world case discussions and interactive Q&A, supporting shared learning and informed clinical decision-making.
This meeting is accredited for 5 CPD points from the Royal College of Pathologists. A certificate of attendance will be shared via e-mail after the event concludes.
Consultant Haematologist specialising in lymphoid malignancies in Oxford, UK. He has completed an MD Doctorate Thesis in 2017. He is an investigator on several national lymphoid trials and has published over 175 peer-review articles on lymphoma and CLL. He is the low grade lymphoma clinical trial research group chair in the UK.
He is a core member of several lymphoma studies groups. He is a member of the BSH guideline writing groups for various lymphoma subtypes. He is an Associate Editor at the British Journal of Haematology. He is the lead author for the new ESMO Lymphoma guidelines.
Chris Stokes is President and General Manager (GM) of Eli Lilly and Company UK, Ireland & Northern Europe, and was appointed to the role in July 2024. Chris leads Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. His 15-year career at Lilly includes roles as GM of Eli Lilly and Company Korea, South Africa & Sub-Saharan Africa, as well as Chief Operating Officer (COO) Lilly USA. Chris holds a Bachelor’s degree from George Mason University and a Master’s in Public Administration from Indiana University-Bloomington.
Consultant Haematologist at the University Hospitals Dorset since 2010. She qualified in Sheffield and completed her specialist haematology training in Leicester, where she also attained a PhD in identifying and characterising novel markers in CLL. She is an active member of the UK CLL Forum and is part of the writing committee that recently updated the national BSH CLL guidelines; since March 2019, she has been chairing the UK CLL Forum.
She is an invited clinical advisor to the Evidence Review Group for NICE appraisals. In addition to CLL, she has developed an interest in Splenic Marginal Zone Lymphoma. She led the first guideline for MZL. Renata Walewska is a member of the NCRI CLL Low Grade NHL subgroup and also collaborates internationally with colleagues developing trials in SMZL. She remains active in scientific research and holds an honorary contract with Southampton University.
Dr El-Sharkawi was appointed as a Consultant Haematologist at the Royal Marsden Hospital in 2017. Her sub-specialist interest is in the management of patients with lymphoma, CLL and mature lymphoid leukaemias. She is clinical lead for the Specialist Integrated Haematological Malignancy Diagnostic Service at the Royal Marsden. She is an investigator on numerous clinical trials in lymphoma and CLL.
She is chair of the BSH haem-onc taskforce responsible for overseeing the guidelines written on the treatment of malignancy haematological disease and has been an author on numerous guidelines. She is a active member in numerous lymphoma study groups and part of the CLL executive committee.
Jack has been a CLL and Lymphoma Clinical Nurse Specialist for the past four years. He qualified around ten years ago and has worked at The Royal Marsden Hospital since qualification.
George Follows received his medical degree from Oxford University Medical School and completed his medical and haematology training in Newcastle and Edinburgh, and his PhD at Leeds University. After a period of post-doctoral research at Cambridge University he was appointed as the Clinical Lead for lymphoma, CLL and clinical trials at Cambridge University Hospitals. He is a former chair of the UK CLL Forum and CLL Guidelines Panel and currently chairs the UK Hodgkin Lymphoma Guidelines Panel.
Professor Follows is the Visiting Professor of Haematology of the Anglia Ruskin Medical School and Associate Professor of Haematology at the University of Cambridge. He continues to work closely with partners in the pharmaceutical and biotechnology sectors and has authored/co-authored over 100 peer-reviewed papers in different areas of haematological biology and therapeutics in journals, including the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Nature, Cell, and Nature Genetics.
Dr Talha Munir is a Consultant Haematologist at Leeds Teaching Hospitals NHS Trust with specialised expertise in CLL, bone marrow failure syndromes, and rare histiocytic disorders. He graduated from King Edward Medical College, Lahore, in 2002 and completed his early medical training in Pakistan before joining the NHS in 2004. Dr Munir undertook specialist haematology training in Nottingham, completing it in 2012. He earned his PhD from the University of Leeds in 2021, focusing on the mechanisms of action of B cell receptor antagonists in chronic lymphocytic leukaemia. His main clinical and research interests centre on CLL, particularly the evaluation of novel targeted therapies.
Dr Munir is also a consultant within the PNH National Service in Leeds, managing patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. In addition, he has a strong interest in the care of adults with histiocytic disorders, including Langerhans cell histiocytosis and Erdheim–Chester disease. He serves as chief investigator for several UK Phase II and III CLL trials and has contributed significantly to expanding the clinical trial portfolio at Leeds. He was recently appointed Deputy Chair of the UK CLL Sub Group, supporting national research and guideline development.
Consultant Haematologist, Honorary Clinical Senior Lecturer and NRS Research Fellow at the Beatson West of Scotland Cancer Centre, where he specialises in lymphoma. He completed haematology training in Glasgow, during which he undertook a lymphoma fellowship and subsequently completed a research doctorate in the field of CNS prophylaxis for diffuse large B-cell lymphoma.
He currently holds the positions of deputy chair of the BSH haemato-oncology task force and Early Career Researcher with the UK High grade lymphoma research group. He has a keen interest in clinical trials and research, with a number of publications and presentations at international meetings.
All questions are moderated by Lilly
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor.
Jaypirca® has been authorised under a "conditional approval" scheme. For more details please see the SmPC.
Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000
Any third-party links contained in this platform will take you to a site maintained by a third party that is solely responsible for its contents. Eli Lilly and Company does not control or endorse these websites and is not responsible for their privacy policies.
Jaypirca® and Lilly are registered trademarks of Eli Lilly and Company.© 2026 Eli Lilly and Company. All Rights Reserved.
Lilly Privacy Policy
Production bureau Privacy Policy
CMAT-11195 March 2026